GlassScriptPhysician profile
Douglas Cipkala
NPI 1760494934
$288.14
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.32 · 2022: $19.75 · 2023: $155 · 2024: $48.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $203.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $54.87 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.70 | 2019-2023 | |
| Servier Pharmaceuticals LLC | $35.45 | 2019-2023 | |
| Alexion Pharmaceuticals, INC. | $29.56 | 2024 | Ultomiris |
| Y-Mabs Therapeutics, INC. | $24.53 | 2023 | Danyelza |
| Rigel Pharmaceuticals, INC. | $24.30 | 2023 | Rezlidhia, Tavalisse |
| Silvergate Pharmaceuticals, INC. | $19.84 | 2019 | |
| Amgen INC. | $19.75 | 2022 | |
| Adaptive Biotechnologies Corporation | $18.50 | 2024 | Clonoseq |
| Helsinn Therapeutics (U.S.), INC. | $12.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Cipkala listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.